Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × mirdametinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 3 Neurofibromatoses 2 Neurofibroma 2 Vascular Malformations 1 Skin Diseases, Vascular 1 Neurofibroma, Plexiform 1 Melanoma 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Glioma 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Arteriovenous Malformations 1

Interventions

Temozolomide 69 Bevacizumab 40 Radiotherapy 22 Magnetic Resonance Spectroscopy 19 Irinotecan 17 Specimen Handling 10 Carboplatin 10 Carmustine 9 X-Rays 7 Radiation 7 olaparib 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Nivolumab 6 Everolimus 6 Cyclophosphamide 6 Biopsy 6 trametinib 5 Thalidomide 5 Cisplatin 5 pembrolizumab 4 palbociclib 4 erdafitinib 4 dabrafenib 4 Lomustine 4 Etoposide 4 Drug Therapy 4 Doxorubicin 4 Aminolevulinic Acid 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07521657 2026-04-13

NF118

University of Alabama at Birmingham

Phase 2 Not yet recruiting

Glioblastoma, Glioma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡